Day One of #BLADDR24 Dr Badrinath Konety Can AI drive treatment decision-making in NMIBC? Growing role of AI in non-muscle invasive bladder cancer care @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of #BLADDR24 Dr Eva Maria Compérat Role of AI for diagnosis and monitoring #BladderCancer Emphasizes the broad potential of AI in diagnosing and monitoring @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of #BLADDR24 Dr Maria De Santis MIBC ESMO congress highlights #BladderCancer Perioperative durvalumab to neoadj gemcitabine & cisplatin improves EFS & OS, w/o delays in radical cystectomy @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of #BLADDR24 Dr Petros Grivas Debate: Role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer Presentation discusses if TOMBOLA is practice changing, and more data is needed @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of #BLADDR24 Dr Cédric Lebâcle Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? "pro" side: adapted de-intensification strategy offers several benefits. @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day 1 of #BLADDR24 Dr Kilian Gust Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? CON While de-intensification and surveillance in low-grade NMIBC may be appealing, it is premature @drnataliagandur.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social

Day One of #BLADDR24 Dr. Ben-Max de Ruiter High-risk BCG-naive NMIBC: should we stick to BCG? @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of hashtag#BLADDR24 Presenter: Dr. Petros Grivas High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC? @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day 1 of #BLADDR24 Dr Celena Scheede-Bergdahl RC & neobladder Prehabilitation programme Prehabilitation in cancer care takes place between diagnosis & start of acute tx, focusing on physical & psychological assessments @drnataliagandur.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social

Study explores how integrated stress response helps #ProstateCancer cells survive, particularly those lacking the p53 tumor suppressor. @yukselurun.bsky.social @drnataliagandur.bsky.social @barbaramelao.bsky.social @oncoalert.bsky.social www.science.org/doi/10.1126/...

Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨

Day One of #BLADDR24 Dr Gunhild von Amsberg Presentation on first-line treatment for advanced urothelial carcinoma highlights the need to balance efficacy, safety, patient characteristics,& QoL. @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Observational study published in JCO found annual screening mammography reduces risk of late-stage #BreastCancer & improves OS VS biennial or intermittent screening https://buff.ly/3Z1GBCw @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @stoverlab.bsky.social @drsgraff.bsky.social

The OncoAlert Network along with our partners at @ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg and our Collaborators @APCCC_Lugano @ABCGlobalAll @kidneycan @GuardConsortium @mybsmo @gu_onc Proudly Announce the first 2/3 of our faculty Register for FREE HERE: https://buff.ly/3CChgre

Proponents of deferred CN argue a complete pathological response in the 1ry tumor is rare, and even in cases of complete response at metastatic sites, viable tumor cells may remain in the 1ry site. Removing the primary tumor might help eliminate rapidly metastasizing clones #RenalC24 🚨 #kidneyCancer

Dr. Barthelemy, Moving forward, identifying biomarkers like KIM1 and T-effector gene expression signatures could help predict which patients are more likely to benefit from therapy. The need for predictive algorithms to assess efficacy and toxicity is clear #kidneyCancer #RenalC24 🚨

Day 1 of #BLADDR24 Dr. Petros Grivas The concept of withholding radical treatment, such as radical cystectomy (RC) or radiotherapy, for patients with a clinical complete response (cCR) after neoadjuvant or induction systemic therapy is emerging as a potential future approach in #BladderCancer MGt

Study explores how the integrated stress response helps prostate cancer cells survive, particularly those lacking the p53 tumor suppressor. Inhibiting the ISR kinase GCN2 in p53-deficient #ProstateCancer cells disrupts amino acid availability, crucial for purine nucleotide synthesis

Dear Colleagues A Pleasure to introduce some our #OncoAlertAF Associate Faculty 🚨 @elisaagostinetto.bsky.social 🇧🇪 @elisabettabonzano.bsky.social 🇮🇹 @realbowtiedoc.bsky.social 🇺🇸 @biagioricciutimd.bsky.social 🇺🇸 @weoncologists.bsky.social 🇺🇸 @drnataliagandur.bsky.social 🇦🇷

Omitting biopsy in pts with negative MRI results eliminated more than 1/2 of diagnoses of clinically insignificant #ProstateCancer and the associated risk of having incurable cancer diagnosed at screening or as interval cancer was very low @drnataliagandur.bsky.social @barbaramelao.bsky.social

OA RoundUp🚨Nov 15-21 youtu.be/BDg6UDh2WvE @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @agerikssonmd.bsky.social @fernandoonco.bsky.social @icromeattini.bsky.social @drnataliagandur.bsky.social @biagioricciutimd.bsky.social @yukselurun.bsky.social

Day 1🚨 #RENALC24 Dr. Bernadett Szabados Metastatic RCC KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social Register https://buff.ly/3Z4aEt3

Day One of #RENALC24 Dr. Philippe BARTHÉLÉMY High-risk RCC after nephrectomy & oligometastatic RCC Risk assessment of post-nephrectomy patients @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social #KidneyCancer Register: https://buff.ly/3Z4aEt3

Day 1 of #RENALC24 Dr. Axel Bex High-risk RCC after nephrectomy and oligometastatic RCC To operate or not? Debate on deferred cytoreductive nephrectomy @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social Register: https://buff.ly/3Z4aEt3

Day 1 of #RENALC24 Dr.Pickering Treatment options in metastatic papillary RCC #KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Day One of #RENALC24 Dr. Philippe BARTHÉLÉMY Looking ahead: RCC management in 2025 Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes. #KidneyCancer @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social

2 Million Impressions on the first ever #RenalC24 Congratulations to our Collaborators at Mirrors of Medicine JOIN US TOMORROW for Day One of #BLADDR24 WE ARE @OncoAlert 🚨 @drnataliagandur.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social

Come & join us for #BLADDR24 - not only updates of the latest science, but important discussion of their impact on clinical practice @oncoalert.bsky.social

OncoAlert and partners (ESSO, ESGO, MASCC & SIOG) Proudly Announce 2/3 of our faculty, more soon Register HERE buff.ly/3CChgre @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @erikahamilton9.bsky.social @agerikssonmd.bsky.social @drjnaidoo.bsky.social

Elucidating acquired PARP inh resistance sciencedirect.com/science/arti... Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬 @drnataliagandur.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social @yukselurun.bsky.social

The @OncoAlert 🚨Newsletter Covering September Nov 14-21, 2024 REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0 ✅ Goteborg 🇸🇪in #prostatecancer ✅Matching to Clinical trials w/GPT💻 ✅PULSAR: ☢️Ultra-fractionated Stereotactive Adaptive RT in CNS ✅CHIPOR ✅EXENTORCH 🫁 #SCLC ✅TITAN

More daily: @mazietsangmd.bsky.social @drteplinsky.bsky.social @jamesfanwu.bsky.social @drnataliagandur.bsky.social @ryannipp.bsky.social @drbonillaonc.bsky.social @subatomicdoc.bsky.social

OncoAlert along with our partners at ESSO, ESGO, MASCC & SIOG Proudly Announce 1/3 of our faculty, more soon@ Register HERE https://buff.ly/3CChgre @elisabettabonzano.bsky.social @elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @erikahamilton9.bsky.social @agerikssonmd.bsky.social